Spatiotemporal AMPKα2 deletion in mice induces cardiac dysfunction, fibrosis and cardiolipin remodeling associated with mitochondrial dysfunction in males only
Authors:
- Lucile GrimbertLGLucile Grimbert
- Maria-Nieves SanzMSMaria-Nieves Sanz
- Mélanie GressetteMGMélanie Gressette
- Catherine Rucker-MartinCRCatherine Rucker-Martin
- Marta NovotovaMNMarta Novotova
- Audrey SolgadiASAudrey Solgadi
- Ahmed KarouiAKAhmed Karoui
- Susana GomezSGSusana Gomez
- Kaveen BedouetKBKaveen Bedouet
- Eric JacquetEJEric Jacquet
- Christophe LemaireCLChristophe Lemaire
- Vladimir VekslerVVVladimir Veksler
Open Access
- 17 September 2021
- journal article
- research article
- Published by Springer Nature in Biology of Sex Differences
- Vol. 12 (1) , 1-24
Abstract
Background: The AMP-activated protein kinase (AMPK) is a major regulator of cellular energetics which plays key role in acute metabolic response and in long-term adaptation to stress. Recent works have also suggested non-metabolic effects. Methods: To decipher AMPK roles in the heart, we generated a cardio-specific inducible model of gene deletion of the main cardiac catalytic subunit of AMPK (Ampkα2) in mice. This allowed us to avoid the eventual impact of AMPK-KO in peripheral organs. Results: Cardio-specific Ampkα2 deficiency led to a progressive left ventricular systolic dysfunction and the development of cardiac fibrosis in males. We observed a reduction in complex I-driven respiration without change in mitochondrial mass or in vitro complex I activity, associated with a rearrangement of the cardiolipins and reduced integration of complex I into the electron transport chain supercomplexes. Strikingly, none of these defects were present in females. Interestingly, suppression of estradiol signaling by ovariectomy partially mimicked the male sensitivity to AMPK loss, notably the cardiac fibrosis and the rearrangement of cardiolipins, but not the cardiac function that remained protected. Conclusion: Our results confirm the close link between AMPK and cardiac mitochondrial function, but also highlight links with cardiac fibrosis. Importantly, we show that AMPK is differently involved in these processes in males and females, which may have clinical implications for the use of AMPK activators in the treatment of heart failure.Keywords
Funding Information
- Fondation de France (00086500)
- Fondation pour la Recherche Médicale (DPM20121125546)
- ERA-CVD (ANR-19-ECVD-0007-01)
- CORDDIM (cod110153)
- Stefanik (35814NK)
- Slovak Research and Development Agency Grant (APVV-15-0302)
- Slovak Scientific Grant Agency (VEGA 2/0091/19)
This publication has 64 references indexed in Scilit:
- Regulation of NAD(P)H oxidases by AMPK in cardiovascular systemsFree Radical Biology and Medicine, 2012
- Resveratrol Improves Survival, Hemodynamics and Energetics in a Rat Model of Hypertension Leading to Heart FailurePLOS ONE, 2011
- Deficiency in AMP-activated protein kinase exaggerates high fat diet-induced cardiac hypertrophy and contractile dysfunctionJournal of Molecular and Cellular Cardiology, 2011
- AMP Activated Protein Kinase-α2 Deficiency Exacerbates Pressure-Overload–Induced Left Ventricular Hypertrophy and Dysfunction in MiceHypertension, 2008
- AMPK Phosphorylation of Raptor Mediates a Metabolic CheckpointMolecular Cell, 2008
- AMP-Activated Protein Kinase α2 Deficiency Affects Cardiac Cardiolipin Homeostasis and Mitochondrial FunctionDiabetes, 2007
- Mitochondrial Respiratory Chain Supercomplexes Are Destabilized in Barth Syndrome PatientsJournal of Molecular Biology, 2006
- Blue native PAGENature Protocols, 2006
- New targets of AMP-activated protein kinaseBiochemical Society Transactions, 2003
- The α1 and α2 isoforms of the AMP‐activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitroFEBS Letters, 1996